Business Description
Panbela Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US69833W4042
Share Class Description:
STU:X70: Ordinary SharesDescription
Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History |
|---|
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-Forward-EBIT | -0.08 | |||||
EV-to-Forward-EBITDA | -0.08 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Panbela Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -17.164 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -35.58 | ||
| 3-Year Sortino Ratio | -3.45 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 119.4 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 119.4 - 119.4 | ||
| Shares Outstanding (Mil) | 4.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Panbela Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Panbela Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 | In 115 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 115 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-24 | In 3 days | ||
| Second quarter earnings results for 2026 | 2026-07-24 | In 3 days | ||
| First quarter earnings conference call for 2026 | 2026-07-17 | 119.40 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-07-17 | 119.40 (+0.00%) | ||
| Third quarter earnings conference call for 2024 | 2024-11-14 16:30 | 119.40 (+0.00%) | ||
| Third quarter earnings results for 2024 | 2024-11-14 | 119.40 (+0.00%) | ||
| Second quarter earnings conference call for 2024 | 2024-08-13 16:30 | 119.40 (+0.00%) | ||
| Second quarter earnings results for 2024 | 2024-08-13 | 119.40 (+0.00%) |
Show
Entries
Panbela Therapeutics Inc Frequently Asked Questions
What is Panbela Therapeutics Inc(STU:X70)'s stock price today?
The current price of STU:X70 is €119.40. The 52 week high of STU:X70 is €119.40 and 52 week low is €119.40.
When is next earnings date of Panbela Therapeutics Inc(STU:X70)?
The next earnings date of Panbela Therapeutics Inc(STU:X70) is 2026-07-24 Est..
Does Panbela Therapeutics Inc(STU:X70) pay dividends? If so, how much?
Panbela Therapeutics Inc(STU:X70) does not pay dividend.
Press Release
Articles on Panbela Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers